July 1, 2023 — The news arrived in our inbox yesterday. Drug shortages that have plagued semaglutide and tirzepatide are growing worse, not fading. Novo Nordisk quietly let the word out: those supply shortages are no longer limited to Ozempic and Wegovy. Saxenda is entering a prolonged period of shortage. So it now appears that constrained supply, high prices, […]
June 3, 2023 — In case you missed it, the framework for obesity care is in the midst of great change. The availability of medicines that actually work to an extent never seen before is causing everyone to question presumptions that researchers and specialists have known to be false for some time. But these great changes are giving rise […]
February 3, 2023 — This is a story that’s been on repeat for well over a year. Novo Nordisk announced its business results for the full year of 2022 this week and declared that supply issues with Wegovy are over – almost. But the fact is that it’s not at all clear that the problem of supply shortages for […]
December 31, 2022 — “It’s difficult to make predictions, especially about the future.” With this anonymous piece of wisdom in mind, it still makes sense to take a moment to look back at the trends that we hoped and expected to shape the year we complete today. So here’s a narrative report card on our 2022 trend predictions. You, […]
December 30, 2022 — CNN, we’re looking at you. Your story claiming that “people with diabetes pay the price” for semaglutide use in obesity is problematic. The story falsely describes the demand for semaglutide as “a hot new weight loss fad.” That is simply wrong. Providing medical care for people who are trying to deal with the complex chronic […]
December 15, 2022 — If nothing else, the last few years have transformed global supply chains from an arcane business concern into something that touched everyone. Setting aside toilet paper and electronics, let’s think for about moment about a supply chain that will be a problem stretching into the coming year – the supply chain for obesity care. How […]
November 7, 2022 — There’s a clue in the strained supply of new obesity and diabetes meds that most everyone is missing. For more than a year now, Novo Nordisk has been unable to produce and distribute an adequate supply of semaglutide in the form of Wegovy for the treatment of obesity. This has knock-on effects. So supply of […]
October 31, 2022 — One of the themes you will hear when ObesityWeek gets underway tomorrow in San Diego is the dramatic progress that’s coming into view with new obesity drugs. But the picture quickly becomes murky in the real world because of issues with supply and access to these new and improved obesity meds. The access to care […]
July 1, 2022 — It’s not just America. The emergence of a highly effective medical treatment for obesity is scrambling the usual approach to obesity all over the world. Because of the disconnect between the biological reality of obesity and popular misconceptions of this disease, healthcare systems typically put people off from getting medical care for it. That approach, […]
